Business
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors
White House Announces “Build Back Better Bill” for Lower Prescription Drug Costs for Americans MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma,
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nWhite House Announces “Build Back Better Bill” for Lower Prescription Drug Costs for Americans\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that its Chief Executive Officer, Mr. James Nathanielsz, believes the Company’s proenzyme therapy may become the healthcare solution of choice for treating cancerous solid tumors. As a result of remarks made by President Biden recently, the White House is determined to help millions of Americans protect and preserve their health, all by making the cost of prescription drugs much more reasonable. Under the “Build Back Better Bill” they plan to end the days when drug companies could increase their prices with no oversight and no accountability. Outrageous costs, affecting everyone across the board, spanning every kind of condition and disease. Mr. Nathanielsz agrees this approach to innovation by the pharma/biotech sector is long overdue and no longer can they set the drug price at whatever the market will bear. The sector must continue to find ways to innovate with new and improved drugs, but not at great expense to the patient. No longer can America afford to subsidize the rest of the world in healthcare.\n\nProenzymes are from naturally derived, bovine sources, extracted and purified to pharmaceutical standards. Thus, a ready-made commercial supply is available, significantly reducing the cost of goods compared to most groundbreaking cancer therapies which are scientifically engineered and tailored to patients on an individual basis, like immunotherapy. Additionally, no serious or severe side effects from proenzyme therapy have been observed to date, compared to standard treatments, which means patients are unlikely required to be admitted to ICU, or even potentially as an inpatient. This could significantly reduce the overall cost burden to the healthcare system and especially to the patient.\n\nMr. Nathanielsz believes that proenzyme therapy could become a long-term approach to the treatment and prevention of metastatic cancer from solid tumors, given the safety profile observed from clinical and non-clinical studies conducted, so far. Furthermore, the ready made commercially availa...